HARROW INC (HROW) Stock Fundamental Analysis
USA - NASDAQ:HROW - US4158581094 - Common Stock
39.62 USD
-0.11 (-0.28%)
Overall HROW gets a fundamental rating of 5 out of 10. We evaluated HROW against 192 industry peers in the Pharmaceuticals industry. HROW has an average financial health and profitability rating. HROW is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year HROW was profitable.
In the past year HROW had a positive cash flow from operations.
In the past 5 years HROW always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: HROW reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of -1.37%, HROW is doing good in the industry, outperforming 75.00% of the companies in the same industry.
HROW's Return On Equity of -10.61% is fine compared to the rest of the industry. HROW outperforms 72.92% of its industry peers.
The Return On Invested Capital of HROW (7.45%) is better than 85.42% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HROW is significantly below the industry average of 13.48%.
The last Return On Invested Capital (7.45%) for HROW is above the 3 year average (1.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.37% | ||
| ROE | -10.61% | ||
| ROIC | 7.45% |
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
1.3 Margins
Looking at the Operating Margin, with a value of 11.23%, HROW belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
HROW's Operating Margin has improved in the last couple of years.
The Gross Margin of HROW (74.56%) is better than 80.21% of its industry peers.
In the last couple of years the Gross Margin of HROW has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.23% | ||
| PM (TTM) | N/A | ||
| GM | 74.56% |
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
2. Health
2.1 Basic Checks
HROW has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
HROW has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HROW has been increased compared to 5 years ago.
Compared to 1 year ago, HROW has an improved debt to assets ratio.
2.2 Solvency
HROW has an Altman-Z score of 3.48. This indicates that HROW is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HROW (3.48) is better than 72.40% of its industry peers.
HROW has a Debt/Equity ratio of 5.17. This is a high value indicating a heavy dependency on external financing.
HROW has a worse Debt to Equity ratio (5.17) than 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.48 |
ROIC/WACC0.81
WACC9.16%
2.3 Liquidity
A Current Ratio of 2.72 indicates that HROW has no problem at all paying its short term obligations.
HROW has a Current ratio (2.72) which is in line with its industry peers.
A Quick Ratio of 2.52 indicates that HROW has no problem at all paying its short term obligations.
HROW has a Quick ratio (2.52) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
HROW shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 109.68%, which is quite impressive.
The Revenue has grown by 47.83% in the past year. This is a very strong growth!
The Revenue has been growing by 31.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%
3.2 Future
Based on estimates for the next years, HROW will show a very strong growth in Earnings Per Share. The EPS will grow by 72.94% on average per year.
The Revenue is expected to grow by 31.80% on average over the next years. This is a very strong growth
EPS Next Y197.23%
EPS Next 2Y148.51%
EPS Next 3Y112.08%
EPS Next 5Y72.94%
Revenue Next Year44.76%
Revenue Next 2Y42.98%
Revenue Next 3Y41.87%
Revenue Next 5Y31.8%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 440.22, HROW can be considered very expensive at the moment.
Based on the Price/Earnings ratio, HROW is valued a bit cheaper than the industry average as 75.52% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of HROW to the average of the S&P500 Index (25.51), we can say HROW is valued expensively.
A Price/Forward Earnings ratio of 21.56 indicates a rather expensive valuation of HROW.
75.52% of the companies in the same industry are more expensive than HROW, based on the Price/Forward Earnings ratio.
HROW is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 34.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 440.22 | ||
| Fwd PE | 21.56 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HROW indicates a somewhat cheap valuation: HROW is cheaper than 78.13% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 35.54 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HROW does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of HROW may justify a higher PE ratio.
HROW's earnings are expected to grow with 112.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.23
PEG (5Y)N/A
EPS Next 2Y148.51%
EPS Next 3Y112.08%
5. Dividend
5.1 Amount
HROW does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HROW (11/19/2025, 2:57:28 PM)
39.62
-0.11 (-0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners57.65%
Inst Owner Change-0.16%
Ins Owners15.72%
Ins Owner Change6.7%
Market Cap1.47B
Revenue(TTM)250.04M
Net Income(TTM)-4.99M
Analysts85.71
Price Target72.13 (82.05%)
Short Float %18.23%
Short Ratio7.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)819.91%
Min EPS beat(2)-18.12%
Max EPS beat(2)1657.94%
EPS beat(4)2
Avg EPS beat(4)222.09%
Min EPS beat(4)-970.3%
Max EPS beat(4)1657.94%
EPS beat(8)3
Avg EPS beat(8)30%
EPS beat(12)4
Avg EPS beat(12)-52.89%
EPS beat(16)5
Avg EPS beat(16)-847.87%
Revenue beat(2)0
Avg Revenue beat(2)-5.01%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)-4.71%
Revenue beat(4)1
Avg Revenue beat(4)-5.43%
Min Revenue beat(4)-17.73%
Max Revenue beat(4)6.04%
Revenue beat(8)2
Avg Revenue beat(8)-3.74%
Revenue beat(12)4
Avg Revenue beat(12)-3.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.63%
PT rev (1m)9.59%
PT rev (3m)15.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.53%
EPS NY rev (1m)10.01%
EPS NY rev (3m)90.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.95%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 440.22 | ||
| Fwd PE | 21.56 | ||
| P/S | 5.86 | ||
| P/FCF | N/A | ||
| P/OCF | 82.94 | ||
| P/B | 31.18 | ||
| P/tB | N/A | ||
| EV/EBITDA | 35.54 |
EPS(TTM)0.09
EY0.23%
EPS(NY)1.84
Fwd EY4.64%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)0.48
OCFY1.21%
SpS6.76
BVpS1.27
TBVpS-3.44
PEG (NY)2.23
PEG (5Y)N/A
Graham Number1.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.37% | ||
| ROE | -10.61% | ||
| ROCE | 9.43% | ||
| ROIC | 7.45% | ||
| ROICexc | 9.93% | ||
| ROICexgc | 45.02% | ||
| OM | 11.23% | ||
| PM (TTM) | N/A | ||
| GM | 74.56% | ||
| FCFM | N/A |
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.66%
ROICexgc(5y)8.29%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexgc growth 3Y16.24%
ROICexgc growth 5YN/A
ROICexc growth 3Y-9.77%
ROICexc growth 5YN/A
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.17 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.27 | ||
| Cap/Depr | 212.17% | ||
| Cap/Sales | 15.3% | ||
| Interest Coverage | 1.18 | ||
| Cash Conversion | 38.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z | 3.48 |
F-Score7
WACC9.16%
ROIC/WACC0.81
Cap/Depr(3y)560.55%
Cap/Depr(5y)363.77%
Cap/Sales(3y)46.48%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)109.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%283.33%
EPS Next Y197.23%
EPS Next 2Y148.51%
EPS Next 3Y112.08%
EPS Next 5Y72.94%
Revenue 1Y (TTM)47.83%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%45.44%
Revenue Next Year44.76%
Revenue Next 2Y42.98%
Revenue Next 3Y41.87%
Revenue Next 5Y31.8%
EBIT growth 1Y427.53%
EBIT growth 3Y69.3%
EBIT growth 5YN/A
EBIT Next Year1336.35%
EBIT Next 3Y239.76%
EBIT Next 5Y132.11%
FCF growth 1Y87.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y306.23%
OCF growth 3YN/A
OCF growth 5YN/A
HARROW INC / HROW FAQ
Can you provide the ChartMill fundamental rating for HARROW INC?
ChartMill assigns a fundamental rating of 5 / 10 to HROW.
What is the valuation status for HROW stock?
ChartMill assigns a valuation rating of 4 / 10 to HARROW INC (HROW). This can be considered as Fairly Valued.
Can you provide the profitability details for HARROW INC?
HARROW INC (HROW) has a profitability rating of 6 / 10.
What are the PE and PB ratios of HARROW INC (HROW) stock?
The Price/Earnings (PE) ratio for HARROW INC (HROW) is 440.22 and the Price/Book (PB) ratio is 31.18.
What is the financial health of HARROW INC (HROW) stock?
The financial health rating of HARROW INC (HROW) is 4 / 10.